Rapamycin (Sirolimus) 化学構造
分子量: 914.18

高品質保証

文献中の引用(59)

カスタマーフィードバック(12)

Quality Control & MSDS

製品説明

  • Compare mTOR Inhibitors
    mTOR製品生物活性の比較
  • 研究分野
  • Combination Therapy
    併用療法

製品の説明

生物活性

製品説明 Rapamycin (Sirolimus) は、特定のmTOR阻害剤で、IC50 が ~0.1 nMです。
ターゲット

mTOR

IC50

~0.1 nM [1]

In vitro試験 Rapamycin inhibits endogenous mTOR activity in HEK293 cells with IC50 of ~0.1 nM, more potently than iRap and AP21967 with IC50 of ~5 nM and ~10 nM, respectively. [1] In Saccharomyces cerevisiae, Rapamycin treatment induces a severe G1/S cell cycle arrest and inhibition of translation initiation to levels below 20% of control. [2] Rapamycin significantly inhibits the cell viability of T98G and U87-MG in a dose-dependent manner with IC50 of 2 nM and 1 μM, respectively, while displaying little activity against U373-MG cells with IC50 of >25 μM despite the similar extent of the inhibition of mTOR signaling. Rapamycin (100 nM) induces G1 arrest and autophagy but not apoptosis in Rapamycin-sensitive U87-MG and T98G cells by inhibiting the function of mTOR. [3]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
HT-29 MXvDfZRwfG:6aXOgRZN{[Xl? MYWxNEBvVQ>? NETyUWY4OiCq MnPTSG1UVw>? MoTKVI91\W62aXH0[ZMh[2GvcITveIhm[2mwLXnu[JVk\WRiY4n0c5RwgGmlaYT5 NV7aZ5dWOjR7MEC4O|M>
HT-29 M{fCXWN6fG:2b4jpZ{BCe3OjeR?= M{DW[|ExKG6P NGnTO5k4OiCq NX\McJl4TE2VTx?= MXnQc5RmdnSrYYTld{BlcWerdH;4bY4ucW6mdXPl[EBkgXSxdH;4bYNqfHl? MlLDNlQ6ODB6N{O=
HT-29 NHPkNo9EgXSxdH;4bYMhSXO|YYm= NIPRVHQyOCCwTR?= NWTzOWM{PzJiaB?= M4K5TGROW09? NHjNXpFRd3SnboTpZZRmeyB3LX\seY9zd3W{YXPpcE1qdmS3Y3XkJIN6fG:2b4jpZ4l1gQ>? NIPtNIszPDlyMEi3Ny=>
PC3 MXfLbY5ie2ViQYPzZZk> M1XGdlExOCCwTR?= NInSZ24yKGh? M2TqT2ROW09? Ml2xVI91\W62bImgbY5pcWKrdIOgcXRQWi2vZXTpZZRm\CCVNjDwbI9{eGixconsZZRqd25id3n0bEBKSzVyIH;mJFwyOCCwTT6= M2fDVFIyQTd6Nkiz
PC3 M2XlXmtqdmG|ZTDBd5NigQ>? MUWxNFAhdk1? MlOyNUBp MXnEUXNQ NWPGeGtCTG:nczDuc5QhcW6qaXLpeEBuXE:ULX3l[IlifGWmIFHreEBxcG:|cHjvdplt[XSrb36= NFrKW3QzOTl5OE[4Ny=>
PC3 NWHMdJJET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXFWpoyNjVizszN NIjSPJEyKGh? MoLvSG1UVw>? MV\JcoR2[2W|IHHueIlxem:uaX\ldoF1cX[nIHHjeIl3cXS7IHHnZYlve3RiaIXtZY4hWEN|IHPlcIx{KHerdHigTWM2OCCxZjC8NVAhdk1? MmHXNlE6Pzh4OEO=
HEK293 MlPLSpVv[3Srb36gRZN{[Xl? M{ixWlExOCCwTR?= M1TWclghcA>? NHSwdY9FVVOR NXPGTVdHUW6qaXLpeJMhXFCDLXnu[JVk\WRiZHXndoFl[XSrb36gc4YhWGSlZESge4l1cCCHQ{WwJI9nKDVyIH7N NXXxcVRrOjF3M{mzNFE>
BT-20 NVfqfZpnU2mwYYPlJGF{e2G7 MnztNlAh|ryP NVvmWJNOTE2VTx?= NGLNcJNFd2W|IH7veEBqdmirYnn0JI1VV1KFMjDk[ZBmdmSnboSgdGFsXCCVNEezJJBpd3OyaH;yfYxifGmxbh?= NIK1V40zOTN3M{W1NS=>
U937 M4[0bGFvfGmkYXP0[ZJq[WxiQYPzZZk> NIG3fZE2OCEQvF2= NF7uUYo1QCCq NV;QeWl4TE2VTx?= Ml;5TY5lfWOnczDhcpRq[mGldHXybYFtKGGldHn2bZR6KGGpYXnud5Qhf2muZDD0fZBmKEynZ3nvcoVtdGFicH7leY1weGirbHGgVIhqdGGmZXzwbIliNTFiSmKzNkBqdiCXOUO3JINmdGy| MoOwNlEyPDJzME[=
U937 NUTwbmo{SW62aXLhZ5RmemmjbDDBd5NigQ>? NHLYSHU2OCEQvF2= NHnJcZM1QCCq M{DjNWROW09? MkPUSI9meyCwb4SgbY5lfWOnIHHueIlj[WO2ZYLpZYwh[WO2aY\peJkh[WejaX7zeEBOUVBicILveIVqdi2mZX\pZ4lmdnRiTHXnbY9v\WyuYTDwcoV2dW:yaHnsZUBLWjN{LUKgbY4hXTl|NzDj[Yxtew>? MX6yNVE1OjFyNh?=
U937 NWXNV5NXSW62aXLhZ5RmemmjbDDBd5NigQ>? M{jqNFUxKM7:TR?= MVi0PEBp NVzuOGpqTE2VTx?= M4DJVGRw\XNibn;0JIlv\HWlZTDhcpRq[mGldHXybYFtKGGldHn2bZR6KGGpYXnud5QhTXOlaHXybYNpcWFiY3;sbUBJSjFyMTDpckBWQTN5IHPlcIx{ MnjvNlEyPDJzME[=
MCF-7 MWTBeZRweGijZ4mgRZN{[Xl? NHG1Vmw{OCCwTR?= MkTzOEBp MmHwSG1UVw>? MoPaTY5lfWOnczDheZRweGijZ4m= NXjvcnN{OjByMkixN|Q>
U87MG MYPLbY5ie2ViQYPzZZk> MXmxJO69VQ>? NGHUc3Q3KGh? M{fJbGROW09? NVzRNlliWG:2ZX70cJkhcW6qaXLpeJMhdVSRUj3t[YRq[XSnZDDTOkBxcG:|cHjvdplt[XSrb36= M4DNUFE6QDR6NEC0
U87MG NEPTR|lMcW6jc3WgRZN{[Xl? M{PSblEh|ryP NYjj[ndHPiCq Mny2SG1UVw>? MofEVI91\W62bImgbY5pcWKrdIOgOGVDWDFqVEewLUBxcG:|cHjvdplt[XSrb36= NWfvdncyOTl6NEi0NFQ>
U87MG NU[1Z|RkU2mwYYPlJGF{e2G7 M3jOWFEh|ryP MWm2JIg> MXPEUXNQ NIWyU|dFd2W|IH7veEBqdmirYnn0JI1VV1JvbXXkbYF1\WRiQXv0JJBpd3OyaH;yfYxifGmxbh?= MX:xPVg1QDRyNB?=
U87MG NXm1S41iU2mwYYPlJGF{e2G7 MUOxJO69VQ>? NFXUUIw3KGh? MoP2SG1UVw>? NV3pe3ZMTG:nczDuc5QhcW6qaXLpeEBRNTSHQmCxLHQ{Py92NjmgdIhwe3Cqb4L5cIF1cW:w NXy0fIxEOTl6NEi0NFQ>
COS7 cells expressing EGFP-HDQ74/rheb MVvBeZRweGijZ4mgRZN{[Xl? MXGwMlIh|ryP Mnf0NlQhcA>? M2fBZmROW09? MkD5TY5lfWOnczDheZRweGijZ4m= MXmxPFM6OTl2OR?=
COS7 cells expressing EGFP-LC3 MVXBeZRweGijZ4mgRZN{[Xl? NX7CZpJ6OC5{IN88US=> NHHBfXIzPCCq MYjEUXNQ NIG0W2ZKdmS3Y3XzJIF2fG:yaHHnfS=> NHuzVogyQDN7MUm0PS=>
H4 MX\GeY5kfGmxbjDBd5NigQ>? NEPzS4sxNjJizszN MnfRNlQhcA>? M4rIdGROW09? MVrJcoNz\WG|ZYOgeIhmKHKjdHnvJI9nKGyrZ3j0JINp[WmwIEOgd5VjfW6rdDCyJJRwKGyrZ3j0JINp[WmwIEOgd5VjfW6rdDCxJIlvKGi3bXHuJGg1KGOnbHzz M17yWlE5ODJ2NUi0
HeLa MYHGeY5kfGmxbjDBd5NigQ>? M4\WU|ExOCCwTR?= M4K4bFM3KGh? M1vjcGROW09? NYnHZ3o1UW6mdXPld{BHWkJiS{KwPVVRNCCWMkC5PGwtKFd{MUCxSkBufXSjboSteYJqeXWrdHnuR{BqdnSncnHjeIlwdg>? M{nEXFE4PTZ|M{i1
HeLa M2PYcmZ2dmO2aX;uJGF{e2G7 MXWxNFAhdk1? NIXRRms{PiCq NXnSelJKTE2VTx?= MXjJcoR2[2W|IF\SRkBYOjFyMV[gcZV1[W62LYXibZF2cXSrblOgbY51\XKjY4Tpc44> NV3XWZRKOTd3NkOzPFU>
HeLa NVvrOpZvTnWwY4Tpc44hSXO|YYm= MmL5NVAxKG6P MkTNN|YhcA>? NF3nOmpFVVOR NYDmOml6UW6mdXPld{BHWkJvRlvCVEBkd22ybHX4JIlvfGW{YXP0bY9v MYCxO|U3OzN6NR?=
SYF NYPNW21oTnWwY4Tpc44hSXO|YYm= MlnhNVAxKG6P NH7pW|AzPCCq MXjEUXNQ MmHYTY5lfWOnczDGVmIuTkuEUDDjc41xdGW6IHnueIVz[WO2aX;u NWroV5dzOTd3NkOzPFU>
SYF NI\QdHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PSe|ExOCCwTR?= MWWyOEBp NWLMOYZbTE2VTx?= MXHJcoR2[2W|IHHueIlxem:uaX\ldoF1cX[nIHHjeIl3cXS7IHHnZYlve3RiU2nGJINmdGy| M4KycVE4PTZ|M{i1
HEK293T NI\HblRCdnSrdnnyZYwhSXO|YYm= NEHIeHMyKG6P M{nvUFQh\A>? M4XNOWROW09? MVfJcoR2[2W|IHHueIl3cXKjbDDhZ5Rqfmm2eTDh[4FqdnO2IFjJWlEhWjVid3n0bEBGSzVyIH;mJFAvOSCwTR?= M{LkPFE4PDh3NUCx
HEK293T Ml3oRY51cX[rcnHsJGF{e2G7 M2S3S|Ehdk1? M{G1eFQh\A>? NXPwbnhGTE2VTx?= NUfpNXVjUW6mdXPld{BidnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJUVZzIGi0JJdqfGhiRVO1NEBw\iByLkOgcm0> M1TmXVE4PDh3NUCx
PBMC NVLDd4F7TnWwY4Tpc44hSXO|YYm= NX3PSWF2OSCwTR?= MlH3NVQh\A>? NYHzO4U5TE2VTx?= NIDRdmFT\WS3Y3XzJGNEWjViZHXud4l1gQ>? MXexO|Q5PTVyMR?=
PBMC NEXke4tHfW6ldHnvckBCe3OjeR?= MV2xJI5O MVqxOEBl M3:5OWROW09? NX;vR|c4TG:nczDuc5Qh[W[oZXP0JGNZS1J2IHTlcpNqfHl? NXnTPWxzOTd2OEW1NFE>
HEK293 cells MVrLbY5ie2ViQYPzZZk> NXP6fG5lPTBibl2= MV[0OUBucW5? NGLI[mpFVVOR NH30WJBKdmirYnn0d{BuXE:UIHvpcoF{\SCjY4Tpeol1gSC5aYToJGlEPTBib3[gNE4yKG6P MV2xO|M2ODl3Mx?=
Drosophila melanogaster S2 cells transfected with N-luc and C-luc Mm\6SpVv[3Srb36gRZN{[Xl? NF3lVosyODBibl2= MYS0JIg> NYDvdZliTE2VTx?= MV3JcoR2[2W|IHz1Z4ln\XKjc3WgdJJwfGWrbjD0doFvey2|cHzpZ4lv\yCrbjDEdo9{d3CqaXzhJI1mdGGwb3fhd5RmeiCVMjDj[YxteyC2cnHud4Zm[3SnZDD3bZRpKE5vbIXjJIFv\CCFLXz1Zy=> M3vKTFE4OTJ6Mk[y
Human mixed lymphocyte NWnEWXRkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nEVFUhdk1? NGHY[HBFVVOR Ml;LTWM2OD1zLk[gcm0v MXGxOlE5PTh4NR?=
Lewis rat lymph node cells NUXJcnZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEWxXZM2KM7:TR?= NGqweJVFVVOR M4Hhd2lEPTB;Mj62JO69VQ>? NXftbmN4OTZzOEW4OlU>
cells from the thymus of normal BALB/c mice M3PzcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HyclExKG6P MV23NkBp MUnEUXNQ MVTJcohq[mm2czDsfY1xcG:ycn;sbYZmemG2aX;uJEhNSUZrIIfpeIghUUN3MDDv[kA{KG6P M4HnVFExODJzOUS4
MRK-nu-1 M1Lm[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILQZYRKSzVyPUCuPFQ2KHCP NGT4dXlUSU6JRWK=
OCUB-M M4HteWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTtTWM2OD13LkK0JJBO MX;TRW5ITVJ?
SF539 NEP2fI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NESwOY5KSzVyPUGxMlYheE1? NX;qSGdDW0GQR1XS
ES4 NV\OeYZQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTJzLkWgdG0> NXrCXJZoW0GQR1XS
RL95-2 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHyxdGNKSzVyPUGwO{BxVQ>? M4[0bXNCVkeHUh?=
LC-2-ad NVTTc3FzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXKS3lKUUN3ME20NlMheE1? MnfxV2FPT0WU
Daudi MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTR|NDDwUS=> NXLU[49xW0GQR1XS
NTERA-S-cl-D1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTR2MzDwUS=> MnOzV2FPT0WU
OS-RC-2 NGG3NYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGL1eXRKSzVyPU[1NkBxVQ>? MnPWV2FPT0WU
VA-ES-BJ NELSdmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTd{MzDwUS=> MnPGV2FPT0WU
GR-ST MoPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTh2NjDwUS=> MnzRV2FPT0WU
SW872 MnnqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHy1UWpKSzVyPUi0OkBxVQ>? MXHTRW5ITVJ?
NOS-1 NIDqW4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HCfGlEPTB;OEexJJBO M3f4e3NCVkeHUh?=
MC116 NX;RZlhST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnWXlFKSzVyPUm4OUBxVQ>? NWXROYN4W0GQR1XS
NCI-H1355 NW[zWJUxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTUbYdKSzVyPUGuNFEhdk1? MlqwV2FPT0WU
RPMI-8226 MnvwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHrWpVxUUN3ME2xMlE6KG6P NHvDc4RUSU6JRWK=
TE-15 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjCcnVKSzVyPUGuN|Yhdk1? MVfTRW5ITVJ?
Ramos-2G6-4C10 MnvXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUj3TphrUUN3ME2xMlQ3KG6P NGWxd21USU6JRWK=
KU812 MnnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPFT5RKSzVyPUKuNFEhdk1? M3zTdHNCVkeHUh?=
EW-1 M1X4Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\mTWM2OD1{LkG3JI5O NXH5XHppW0GQR1XS
KS-1 M{mzWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIP4dYFKSzVyPUKuOFUhdk1? M3jmRXNCVkeHUh?=
SK-LMS-1 M37Fe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGezV4FKSzVyPUKuOFkhdk1? M4TkUXNCVkeHUh?=
TGBC1TKB NXHpc4hUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17ESWlEPTB;Mj62PUBvVQ>? M{HuRXNCVkeHUh?=
TE-6 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmG0TWM2OD1{Lke3JI5O NH;oe4tUSU6JRWK=
ETK-1 M2rUc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWm4c|dkUUN3ME2yMlgzKG6P NGm1Z3hUSU6JRWK=
BE-13 NIjjNVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTJwOUmgcm0> NUi2TlBOW0GQR1XS
A3-KAW NUiyRZo5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfXTWM2OD1{Lkm5JI5O NYjycINZW0GQR1XS
TE-10 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zHemlEPTB;Mz6zJI5O M2PSUHNCVkeHUh?=
DOHH-2 MlO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvQOW9KSzVyPUOuN|Uhdk1? NFyxS2JUSU6JRWK=
ES6 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2G3VmlEPTB;Mz60N{BvVQ>? MX\TRW5ITVJ?
OPM-2 MnjDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF[1bJNKSzVyPUSuNVUhdk1? MXTTRW5ITVJ?
SH-4 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzpXYJ2UUN3ME20MlM1KG6P M1njfXNCVkeHUh?=
NB13 MlzkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vEbWlEPTB;ND6zOkBvVQ>? Ml3zV2FPT0WU
HUTU-80 MnfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4THPWlEPTB;ND60NkBvVQ>? MkS2V2FPT0WU
CCRF-CEM MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjaPFNKSzVyPUSuPVQhdk1? MoHHV2FPT0WU
TGBC24TKB NFfPTGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rqdmlEPTB;NT61NUBvVQ>? MXHTRW5ITVJ?
697 M4PsfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXXcnhKSzVyPU[uNlghdk1? NGPtOpVUSU6JRWK=
J-RT3-T3-5 NXHNZopyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTZwNE[gcm0> MljQV2FPT0WU
KALS-1 NGLVcXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWCzO3d5UUN3ME22MlU3KG6P NF\WSZVUSU6JRWK=
no-10 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjFOodrUUN3ME23MlI6KG6P NX\tbI5EW0GQR1XS
SK-NEP-1 MkPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnFTZhKSzVyPUiuO|khdk1? MnrGV2FPT0WU
L-540 NWWwVFc{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTFyLkSyJI5O MUDTRW5ITVJ?
JiyoyeP-2003 NGDYc3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTFyLkm0JI5O MV\TRW5ITVJ?
HH NFj0Om5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{D1e2lEPTB;MUGuN|khdk1? MX\TRW5ITVJ?
SR NE[3W4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFH4fIhKSzVyPUGxMlQ2KG6P M1Pub3NCVkeHUh?=
QIMR-WIL M1HvNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LNdGlEPTB;MUGuPFUhdk1? MVfTRW5ITVJ?
A4-Fuk MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPZUJhUUUN3ME2xN{4yOiCwTR?= NHTBfYRUSU6JRWK=
CESS NVvWd5hDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTVTWM2OD1zMz6xN{BvVQ>? NYW5cWJsW0GQR1XS
KE-37 MkjIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX:5PIpxUUN3ME2xOk4xPyCwTR?= NEnjeWlUSU6JRWK=
SK-UT-1 M4\mWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XyS2lEPTB;MU[uPFEhdk1? NHfVcY5USU6JRWK=
SIG-M5 NX\VOFlWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTF5LkK1JI5O NVHJSHFtW0GQR1XS
HT M1rIbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLkVlFKSzVyPUG3MlYhdk1? NXTuU|NuW0GQR1XS
DEL MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTF5Lkm5JI5O MmXJV2FPT0WU
SK-PN-DW NIC0cGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjhOGNzUUN3ME2yNE4zOyCwTR?= NVrUNHNrW0GQR1XS
RPMI-8402 M3znbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\LemQyUUN3ME2yNU44PyCwTR?= NH7UbphUSU6JRWK=
RPMI-6666 NV35R5hqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPTcYFKSzVyPUK0MlQzKG6P MYXTRW5ITVJ?
NCI-H720 MoDKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETN[ZNKSzVyPUK1MlQyKG6P M{DaRnNCVkeHUh?=
EW-16 NXr0UW55T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTJ4Lki3JI5O NH\NeoFUSU6JRWK=
BL-70 NX7He4djT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlq3TWM2OD1{OD6zPEBvVQ>? NWXBPIpNW0GQR1XS
SF126 MlTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVi4UYVUUUN3ME2zNE4{QCCwTR?= M3j0b3NCVkeHUh?=
BC-1 NW\O[plYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjnb2xKSzVyPUOxMlI3KG6P MnL2V2FPT0WU
MHH-PREB-1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTN{LkS0JI5O NGTWTo9USU6JRWK=
A101D NFvmTZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTN{Lk[yJI5O MXrTRW5ITVJ?
NMC-G1 M1HNbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHPeIVKSzVyPUOzMlY4KG6P MonKV2FPT0WU
LB1047-RCC M3zRSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTN2Lk[5JI5O MlXiV2FPT0WU
EM-2 M1vz[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TQTGlEPTB;M{iuOVMhdk1? M4TIRnNCVkeHUh?=
COLO-684 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTN7Lkigcm0> MXvTRW5ITVJ?
Becker NFHKVJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PvWmlEPTB;NEGuNFUhdk1? NGP3fJVUSU6JRWK=
BL-41 NHu1OoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfMTWM2OD12Mz62OkBvVQ>? MoXDV2FPT0WU
MDA-MB-134-VI Mn3WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTR2LkCyJI5O NGTWN5JUSU6JRWK=
L-363 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TTcmlEPTB;NESuO|Mhdk1? NH;wbFBUSU6JRWK=
ECC4 NWHJeZN4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDrTWM2OD12ND63PEBvVQ>? MVzTRW5ITVJ?
A388 M3jG[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPrTWM2OD12ND64NkBvVQ>? NGjj[4pUSU6JRWK=
HEL NYK0[W5pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnEbXlMUUN3ME20PU44QSCwTR?= NFzjbJlUSU6JRWK=
RKO M13LPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjMOHFKSzVyPUWwMlI6KG6P NFn0PHZUSU6JRWK=
KINGS-1 MnvOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7zfpdKSzVyPUWxMlU2KG6P NGfqdnlUSU6JRWK=
EB-3 NV\NSnBYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M12yZWlEPTB;NUKuOlchdk1? NF3nUmNUSU6JRWK=
ARH-77 NXv4[3loT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTV{Lkigcm0> MU\TRW5ITVJ?
GCIY MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fZOmlEPTB;NUOuOFYhdk1? Ml:5V2FPT0WU
NCI-H1304 M1jKXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlf5TWM2OD13Nz6yNkBvVQ>? MVTTRW5ITVJ?
KARPAS-299 NGHkNJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljnTWM2OD14MT64NkBvVQ>? M1jsWnNCVkeHUh?=
IA-LM MlvXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnG1TWM2OD14OD6xN{BvVQ>? MoPNV2FPT0WU
GI-1 NULHeVhkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvITWM2OD15MD6zPUBvVQ>? NU\hO21jW0GQR1XS
TE-11 NF;LZ4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTd5LkG3JI5O NVG0VHNQW0GQR1XS
LS-411N NWPPeY55T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1L4PWlEPTB;N{euOVchdk1? M3y3S3NCVkeHUh?=
no-11 M2jjPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTh|LkK0JI5O MWPTRW5ITVJ?
MV-4-11 NFzzXo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7tTWM2OD16Mz63N{BvVQ>? M{[xOHNCVkeHUh?=
BV-173 NX7FcXdJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrk[pZNUUN3ME24N{46PyCwTR?= M4r1dXNCVkeHUh?=
CMK MlXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTh2LkG2JI5O M4DzTHNCVkeHUh?=
LC4-1 MkiwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3f4ZmlEPTB;OE[uO|Ihdk1? NX\PbI9oW0GQR1XS
COR-L279 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2C1bmlEPTB;OEeuNlUhdk1? MYTTRW5ITVJ?
NCI-H209 M2T6[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGruV3NKSzVyPUi3MlQyKG6P NGPI[YtUSU6JRWK=
Raji NGPTXJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTh7LkeyJI5O MoDHV2FPT0WU
LB996-RCC MoOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPKTWM2OD17Mz60N{BvVQ>? NH;vPVhUSU6JRWK=
NCI-H526 NXH1NWdzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDoeVk4UUN3ME25N{42QSCwTR?= MXrTRW5ITVJ?
KGN M{W3R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWK1bmZiUUN3ME25Ok4zQSCwTR?= MlvkV2FPT0WU
MOLT-4 NYm1fFk{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHkemlKSzVyPUm2Mlc6KG6P NH7uPJhUSU6JRWK=
PF-382 M{GxVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjRW3B3UUN3ME25Ok44QSCwTR?= M3ywXXNCVkeHUh?=
BC-3 NX[ySnZTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPJTWM2OD17OT6xPEBvVQ>? NY\FfJBHW0GQR1XS
KARPAS-422 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTFyMj6wPUBvVQ>? NVf0e452W0GQR1XS
SBC-1 NHyzb4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlviTWM2OD1zMEeuO|Uhdk1? M3fobnNCVkeHUh?=
LC-1F MoL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTFyOD6wOUBvVQ>? NVLmRnkxW0GQR1XS
GB-1 M{fyR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;oT2lEPTB;MUC5MlAzKG6P NXPXSYtNW0GQR1XS
SNB75 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfOTWM2OD1zMUmuOlkhdk1? Mnm4V2FPT0WU
BB65-RCC MoTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTFzOT65N{BvVQ>? NFXVO2dUSU6JRWK=
NCI-N87 NIm4c2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEWxbXlKSzVyPUGyNU46QCCwTR?= M4fSfnNCVkeHUh?=
IST-MEL1 Mm[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPPc5o4UUN3ME2xNlIvOzhibl2= M1O1VXNCVkeHUh?=
HOP-62 M1nh[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXoUHRFUUN3ME2xNlYvQDlibl2= NHLvc2NUSU6JRWK=
ACN NGezWHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHDVZF2UUN3ME2xOFYvPzVibl2= NGPKSWhUSU6JRWK=
DMS-114 NXfNVlVYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPpZo9KSzVyPUG1NE43PyCwTR?= M4Gw[nNCVkeHUh?=
MLMA M3zLT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH24NWxKSzVyPUG1PU45QCCwTR?= NXfSVZF6W0GQR1XS
HT-144 M{PwUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mly1TWM2OD1zNkWuOFMhdk1? M{\BSHNCVkeHUh?=
C2BBe1 NXrGeZhKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVX0S446UUN3ME2xOlcvPzZibl2= MUTTRW5ITVJ?
L-428 NG[wNGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LoTGlEPTB;MUe3Mlchdk1? MXfTRW5ITVJ?
DU-4475 M1zsfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzwTWM2OD1zOEeuOlghdk1? MUTTRW5ITVJ?
CP67-MEL MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTF7OT6zPEBvVQ>? MWrTRW5ITVJ?
MEG-01 NX\MbWRUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fzVmlEPTB;MkCxMlk3KG6P MmrYV2FPT0WU
IST-SL2 Ml3IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHIN5pmUUN3ME2yNFgvPjNibl2= MUfTRW5ITVJ?
ES8 NVns[Y1wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYm4V4l5UUN3ME2yNlUvQTRibl2= NWTDOWoxW0GQR1XS
COLO-800 MmHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmX5TWM2OD1{M{WuNlghdk1? NIfSXJdUSU6JRWK=
MFH-ino MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXqUZlKSzVyPUKzOU45PCCwTR?= NUPGcndsW0GQR1XS
OVCAR-4 NVPITZBWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrFTWM2OD1{M{euNlQhdk1? NW\IPFQ4W0GQR1XS
PSN1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;Z[GtKSzVyPUK0Nk44OSCwTR?= MlTuV2FPT0WU
EW-12 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEewcYFKSzVyPUK0N{4yKG6P NHrPTJlUSU6JRWK=
HCC1599 NHf5UpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\XfoJKSzVyPUK2NU41PyCwTR?= MVXTRW5ITVJ?
SJSA-1 NYLVZW4zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvzOGZKSzVyPUK3NU41PiCwTR?= MWTTRW5ITVJ?
ST486 MkewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTJ7Nj6xOEBvVQ>? M4nZZ3NCVkeHUh?=
NOMO-1 Mk\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPlbVJKSzVyPUOwNE4zOSCwTR?= M2jhTnNCVkeHUh?=
MN-60 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvKVmZKSzVyPUOwOU4{OiCwTR?= MUTTRW5ITVJ?
HCC1187 NWrUWItHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;DVGFUUUN3ME2zNFcvOjVibl2= M{njWHNCVkeHUh?=
SW982 NF7rNIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fqPWlEPTB;M{G0Mlc2KG6P M{jkSHNCVkeHUh?=
LB647-SCLC NYPaW5h1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFX5RmRKSzVyPUOyPE44OSCwTR?= NXfMWW52W0GQR1XS
HC-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHETWM2OD1|M{WuOUBvVQ>? NIHwT49USU6JRWK=
EHEB MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrEPXVKSzVyPUOzO{42OiCwTR?= M1r6NHNCVkeHUh?=
TUR NV7RdGx6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTN4Mz65OUBvVQ>? NUPuNXlIW0GQR1XS
LU-139 NUfDUmpOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nXUWlEPTB;M{e4MlAzKG6P MVrTRW5ITVJ?
NB1 M2qxcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTJTWM2OD1|OESuOFUhdk1? MoO3V2FPT0WU
BB30-HNC NIX6eW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrpTWM2OD1|OEiuN|Ihdk1? MUfTRW5ITVJ?
HAL-01 M2jXRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTN6OT6yOkBvVQ>? MVrTRW5ITVJ?
K5 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjm[FBKSzVyPUSxNU4{PyCwTR?= MVLTRW5ITVJ?
MZ2-MEL NHvDdIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7VeIhIUUN3ME20NVMvPjRibl2= NEHzOG1USU6JRWK=
RXF393 Mn;VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDDVndKSzVyPUSxOk41PSCwTR?= NYjyUIJKW0GQR1XS
NCI-H1648 Mo\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHrdHpjUUN3ME20NVcvPTNibl2= MlrIV2FPT0WU
TE-12 M1HH[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfjVGVTUUN3ME20N|QvOjZibl2= NGHsbYFUSU6JRWK=
EoL-1- MlHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\4VIZ6UUN3ME20N|cvQThibl2= NInO[JZUSU6JRWK=
JAR NWnhXoptT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHqyRm5KSzVyPUSzPE43OiCwTR?= NIf1cVJUSU6JRWK=
DSH1 MkDYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHFOpRKSzVyPUS1PE46OSCwTR?= NXLYSJNuW0GQR1XS
NCI-H187 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHzTWM2OD12NkKuPFEhdk1? MWHTRW5ITVJ?
HCE-4 NFu4[I9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LFNWlEPTB;NEe3MlY3KG6P NHe5PFZUSU6JRWK=
8-MG-BA MlniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTV6MT61NkBvVQ>? MY\TRW5ITVJ?
KLE MlTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfkPFRFUUN3ME21PFUvOiCwTR?= MXHTRW5ITVJ?
KNS-42 M37lUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWi2WXFsUUN3ME21PFYvQDFibl2= M3z4fHNCVkeHUh?=
MSTO-211H M{i3e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TPTWlEPTB;NkC5Mlc1KG6P NHmxVXZUSU6JRWK=
GDM-1 MnPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFy1ZXZKSzVyPU[xOE4xQSCwTR?= MVvTRW5ITVJ?
TE-1 NVnoTlhJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWraVGlKUUN3ME22OFYvOTJibl2= M{X3W3NCVkeHUh?=
BT-474 NH7jWFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzFflRKSzVyPU[0O{4xPiCwTR?= MVrTRW5ITVJ?
KARPAS-45 MlfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zrSGlEPTB;NkS3MlYhdk1? NX6xN4ZCW0GQR1XS
MOLT-16 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHiOHoxUUN3ME22OFcvQTNibl2= MUjTRW5ITVJ?
KURAMOCHI NH;W[WhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTsTWM2OD14NUeuOVEhdk1? M1jZcXNCVkeHUh?=
K-562 MkH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlmxTWM2OD14NkmuOVEhdk1? NY\rbGdUW0GQR1XS
EKVX M2PIXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWizemhWUUN3ME22O|IvPzFibl2= NULoTWM4W0GQR1XS
GAK NVrpfmdZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nYdWlEPTB;Nke1MlMhdk1? MXvTRW5ITVJ?
NCI-SNU-5 M4\Semdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jiSmlEPTB;NkmwMlAyKG6P M33PRnNCVkeHUh?=
NCI-H2126 NWDIZ4RXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TwS2lEPTB;N{K2Mlg4KG6P MlvuV2FPT0WU
CTV-1 MkLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PkbWlEPTB;N{S0Mlkhdk1? MWjTRW5ITVJ?
SW962 MnvGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnOW3M1UUN3ME23OFgvPDRibl2= M3rrVnNCVkeHUh?=
MONO-MAC-6 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDZVGs5UUN3ME23OVYvQTNibl2= M3nueHNCVkeHUh?=
NCI-H748 NXzI[oNiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzxTWM2OD15NUiuPVkhdk1? NXjDdZF6W0GQR1XS
NCI-H524 NX3Je2MxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nEWGlEPTB;N{iwMlc{KG6P Mlq4V2FPT0WU
LS-123 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUmySJdxUUN3ME23PVUvPjlibl2= NEPIOlBUSU6JRWK=
NB7 M3vQVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7CeXNKSzVyPUixOE4yPCCwTR?= MYXTRW5ITVJ?
LS-1034 NIDpemZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTh{OD65PEBvVQ>? M37E[XNCVkeHUh?=
TE-5 M3f3Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTh6Mz61OkBvVQ>? MonyV2FPT0WU
A704 MkP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml36TWM2OD16OUmuNVUhdk1? NIXiRodUSU6JRWK=
TK10 NV:1Z2t[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mom0TWM2OD17MU[uNFMhdk1? MlO1V2FPT0WU
NCI-H345 MlzPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXG1dWQ6UUN3ME25OFMvOjJibl2= M3rGTHNCVkeHUh?=
CGTH-W-1 NUHR[5pST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTl2OD6xN{BvVQ>? MVXTRW5ITVJ?
NCI-H510A M{G5RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PWPWlEPTB;OUi1MlEzKG6P NEHZWIpUSU6JRWK=
NCI-H1963 M1XHWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHLTWM2OD1zLkCzNlkzKM7:TR?= NWDVepdWW0GQR1XS
SCC-3 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPEbW9KSzVyPUGuNFM1OTRizszN MljyV2FPT0WU
EW-11 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrhfmFKSzVyPUGuNFg4PDNizszN MmKwV2FPT0WU
CPC-N MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXr2XZJrUUN3ME2xMlA5QCEQvF2= NVXpbIFoW0GQR1XS
NCI-H1417 NITiO3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTFwMUKyOkDPxE1? M{fvdXNCVkeHUh?=
DG-75 M2DxXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPBTWM2OD1zLkG2Nlg2KM7:TR?= NYe5PZI1W0GQR1XS
HD-MY-Z Mnz2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rvTmlEPTB;MT6xOlQyPiEQvF2= MX7TRW5ITVJ?
ATN-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXHTWM2OD1zLkK2NlA6KM7:TR?= MYnTRW5ITVJ?
KM-H2 MkjKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTFwMk[0NFgh|ryP MVjTRW5ITVJ?
NCI-H2081 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTFwMk[2N|ch|ryP Mmf5V2FPT0WU
HL-60 NF;vXYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHjeWlvUUN3ME2xMlI3QTV7IN88US=> NIfZW3pUSU6JRWK=
DB NG\v[ohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTFwMkeyOFIh|ryP MX\TRW5ITVJ?
NCI-H1522 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmj0TWM2OD1zLkK4PFg4KM7:TR?= NH\qdXNUSU6JRWK=
AM-38 M2[yemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\5R2lEPTB;MT6zNFczKM7:TR?= MoXXV2FPT0WU
NCI-H446 NVTMeXBTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jrZmlEPTB;MT6zNlEzOSEQvF2= MnrZV2FPT0WU
SU-DHL-1 NGTZelRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGqxSIhKSzVyPUGuN|I5ODFizszN M3ThO3NCVkeHUh?=
NH-12 MlvIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXITWM2OD1zLkO2N|c1KM7:TR?= NWHVV2Z6W0GQR1XS
DMS-79 NHX4empIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3oRZNKSzVyPUGuN|Y5PjZizszN NVfRT2lNW0GQR1XS
NCI-H716 NIrDTnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPaTWM2OD1zLkO4PVg3KM7:TR?= M4rCU3NCVkeHUh?=
ML-2 NG[zNWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYj4[GJWUUN3ME2xMlQyPTJ7IN88US=> MmPqV2FPT0WU
NB10 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTFwNE[2N|Ih|ryP M4r3d3NCVkeHUh?=
ONS-76 M4LjOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVT1Tmd4UUN3ME2xMlU{PTZ7IN88US=> M{Sy[3NCVkeHUh?=
LOUCY NHHmR5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTFwNUS2OVch|ryP NFjqPVlUSU6JRWK=
SCLC-21H NWfCUIZXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PV[GlEPTB;MT61PFU5OiEQvF2= MXnTRW5ITVJ?
TGW M1H2cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{f5ZWlEPTB;MT62N|k4PSEQvF2= M2HmVXNCVkeHUh?=
LXF-289 NILJWphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTnTWM2OD1zLkezNlY5KM7:TR?= MkflV2FPT0WU
BB49-HNC M4Hvb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXyTWM2OD1zLkezOVg3KM7:TR?= NGXiPJFUSU6JRWK=
NCI-H747 NHrYbGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrjTWM2OD1zLke1N|Q3KM7:TR?= MoPxV2FPT0WU
LU-165 Mmf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nDdmlEPTB;MT64OFk5PiEQvF2= MXvTRW5ITVJ?
OMC-1 M3G2fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTMW3NGUUN3ME2xMlk2ODZ4IN88US=> Ml3BV2FPT0WU
RCC10RGB NGL2[IlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTFwOUW4NVch|ryP NXLnTGt{W0GQR1XS
SW684 NIDqPYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTFwOU[wPVkh|ryP NYPtZpNlW0GQR1XS
TE-8 MkDFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH36VGZKSzVyPUKuNFU2PTlizszN MV3TRW5ITVJ?
SK-N-DZ M3jEV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fIXGlEPTB;Mj6xN|I4PCEQvF2= MVzTRW5ITVJ?
EVSA-T MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPsXGhKSzVyPUKuNVc{OTVizszN MoezV2FPT0WU
KASUMI-1 NVGzRY1VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXWOnlMUUN3ME2yMlE5QDF3IN88US=> MU\TRW5ITVJ?
NKM-1 M1\0Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXZcZVYUUN3ME2yMlI2PDd{IN88US=> NIHPe4VUSU6JRWK=
CAL-148 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mke1TWM2OD1{LkOzOlE1KM7:TR?= NYDG[mtwW0GQR1XS
NCI-H64 MmX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTJwM{SyN|Ih|ryP MUDTRW5ITVJ?
KNS-81-FD M3fnemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIG2[5RKSzVyPUKuN|Y3OiEQvF2= NWe3To5rW0GQR1XS
KM12 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTJwNEC4N|kh|ryP Mo\UV2FPT0WU
SW954 M2\6Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUS5THkxUUN3ME2yMlQ4Pzd7IN88US=> NGO4Rm1USU6JRWK=
NCI-H1395 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTJwNUK2OFUh|ryP NHjYXVBUSU6JRWK=
DJM-1 MlTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTJwNkC2N{DPxE1? NFXNcZJUSU6JRWK=
COLO-668 NGPrfY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2T4RWlEPTB;Mj64NlY6PSEQvF2= MoewV2FPT0WU
NCI-H1436 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nZU2lEPTB;Mj64OVYyPSEQvF2= M3zEenNCVkeHUh?=
LB2241-RCC MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\aT4tKSzVyPUKuPFY5OzlizszN MVzTRW5ITVJ?
GT3TKB NFKybJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1O3bGlEPTB;Mj64PVA2PSEQvF2= MXnTRW5ITVJ?
COLO-824 M4TKfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLhSFlKSzVyPUKuPFk4PjhizszN NW[yPWNMW0GQR1XS
ES1 Ml7BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkSwTWM2OD1{Lki5PFc6KM7:TR?= Mn3GV2FPT0WU
LB771-HNC MofCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrOdlJ5UUN3ME2yMlkxQTR4IN88US=> NWGwSFJ6W0GQR1XS
GI-ME-N Moi5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGC1c2FKSzVyPUOuNFA6ODRizszN NEHnN|RUSU6JRWK=
NALM-6 M2L0SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3y4[mlEPTB;Mz6wNFk{OyEQvF2= NYLUXGlnW0GQR1XS
LU-134-A NIX2XFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTNwMEW0NlUh|ryP M1r0T3NCVkeHUh?=
DMS-153 NV3rRVBXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{T2fmlEPTB;Mz6wOVgzPCEQvF2= M17SdXNCVkeHUh?=
MZ1-PC Mo\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlq5TWM2OD1|LkC5NFc5KM7:TR?= M1fHcHNCVkeHUh?=
NCI-H1155 M{HwZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jSeGlEPTB;Mz6xNVYyKM7:TR?= NX7hbVJKW0GQR1XS
CAS-1 M4TsV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TjXmlEPTB;Mz6xN|cxPyEQvF2= NVi3VHk2W0GQR1XS
D-502MG NHr3SYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HVXWlEPTB;Mz6xOFM6KM7:TR?= MYfTRW5ITVJ?
NCI-H2141 M{C1UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnwZW5oUUN3ME2zMlE4PDV{IN88US=> M2n0XHNCVkeHUh?=
NB6 M{PFOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TvTWlEPTB;Mz6xPFI2QSEQvF2= Mn3rV2FPT0WU
NCCIT MmrkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTNwMkG4NFkh|ryP NETNbZdUSU6JRWK=
NB69 Mk\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTNwM{G4PVEh|ryP NVrsUJRVW0GQR1XS
JVM-2 Mn3IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2K2TmlEPTB;Mz6zOlQ{OyEQvF2= NF;KTXNUSU6JRWK=
K052 NXrofmU5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\oW4xKSzVyPUOuN|c6PjhizszN MUjTRW5ITVJ?
HCC2157 NV\1UpN1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTNwNUOyNlgh|ryP MXXTRW5ITVJ?
KMOE-2 NYDSeJZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fjc2lEPTB;Mz61OFI1OiEQvF2= NGj0OY9USU6JRWK=
SF268 Mlf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFz4bJFKSzVyPUOuO|E2PTRizszN NGW5XYRUSU6JRWK=
CHP-126 Mk\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fVTGlEPTB;Mz63OlQ2QCEQvF2= NFzvfplUSU6JRWK=
CP66-MEL NWrwWGtzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjtNZBKSzVyPUOuO|kxQTRizszN M{\BSXNCVkeHUh?=
NCI-H69 Mn[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HDVWlEPTB;ND6wNVk{PiEQvF2= MoTSV2FPT0WU
A253 NEHuOFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HIcmlEPTB;ND6wNlExOSEQvF2= MWnTRW5ITVJ?
NB14 NFqyXGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDJUmdKSzVyPUSuNVA1PzlizszN NGnDUVRUSU6JRWK=
NCI-H1694 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{D4cmlEPTB;ND6xN|EyOiEQvF2= NIfT[G1USU6JRWK=
NCI-H2196 MlLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTRwMUexOlkh|ryP NV34OGlnW0GQR1XS
TE-9 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HLNmlEPTB;ND6xO|U5OiEQvF2= MlK0V2FPT0WU
D-283MED M1\NU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXETWM2OD12LkG4PFQh|ryP NG\NeYpUSU6JRWK=
OCI-AML2 M{HNbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjkTWM2OD12LkG5OFg6KM7:TR?= NWr2RlRbW0GQR1XS
D-263MG NH;WbYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mne3TWM2OD12LkKyPVYyKM7:TR?= MV7TRW5ITVJ?
MPP-89 NHf5V2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fydGlEPTB;ND6yO|MxPCEQvF2= M1z2OnNCVkeHUh?=
LAMA-84 MlW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrifZE2UUN3ME20MlMxPDJzIN88US=> MWrTRW5ITVJ?
LB373-MEL-D MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTRwM{[3PFkh|ryP NFfHTI5USU6JRWK=
UACC-257 M4TOVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTRwM{m1N|Qh|ryP M1WyR3NCVkeHUh?=
MC-CAR MmXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTRwNEO5PUDPxE1? NULGWlJGW0GQR1XS
COLO-320-HSR NFfuOndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUmwZ2hzUUN3ME20MlQ1PDJ5IN88US=> M2X5NHNCVkeHUh?=
P30-OHK MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fwe2lEPTB;ND62OlU5OSEQvF2= MmS3V2FPT0WU
UACC-812 MoDNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILkWGxKSzVyPUSuOlkyPjFizszN MYHTRW5ITVJ?
CTB-1 NYj3NZY3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;rRWNKSzVyPUSuO|E2PTVizszN NHywVY1USU6JRWK=
ALL-PO M2mxR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTRwOESwO|ch|ryP MXTTRW5ITVJ?
SK-MEL-2 M3XkXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEn0RotKSzVyPUSuPFY6PTVizszN NV\Lfoo5W0GQR1XS
TC-YIK MoKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjq[3I4UUN3ME20Mlk4QTR{IN88US=> NUDNU5ZmW0GQR1XS
NCI-H1882 M3LZVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MomyTWM2OD13LkCyNFAyKM7:TR?= MWPTRW5ITVJ?
MHH-CALL-2 Mo\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3q4dWlEPTB;NT6wOVA1OiEQvF2= Mlr3V2FPT0WU
U-87-MG MorzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrUdmpKSzVyPUWuNFk1PjZizszN MnfQV2FPT0WU
NCI-H1092 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;FbGlEPTB;NT6yOlU2PSEQvF2= NUX5Z3JpW0GQR1XS
TE-441-T NGLERoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTVwMke4NkDPxE1? MUXTRW5ITVJ?
SK-MEL-1 M3j6Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTVwMkmwOFQh|ryP MVfTRW5ITVJ?
EW-22 M3nRN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjq[|dKSzVyPUWuNlk1PjZizszN MkHvV2FPT0WU
MZ7-mel NFjRWFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPvd3NKSzVyPUWuOFA3QTFizszN NVXG[HJGW0GQR1XS
LP-1 M{jFeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTVwNEGyPVEh|ryP MVTTRW5ITVJ?
NCI-SNU-16 MlHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\zb3VKSzVyPUWuOlQxPzRizszN NHmzWmxUSU6JRWK=
LU-65 NGDJc5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTVwN{[zO|Mh|ryP NX7TRYc4W0GQR1XS
CW-2 NI[y[WFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\FTWM2OD13Lki1PVU6KM7:TR?= MX\TRW5ITVJ?
WSU-NHL M4Hxdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NID2bFVKSzVyPUWuPVUyPzRizszN M4nNWHNCVkeHUh?=
IST-MES1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETzdIVKSzVyPUWuPVU1PDNizszN NVjvcm84W0GQR1XS
U-266 NF6yeWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTVwOUiyNFIh|ryP NH;Ob4VUSU6JRWK=
TALL-1 MofJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTZwMUS2PFgh|ryP NVz6SG1CW0GQR1XS
Calu-6 NV;OXWdtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Moi5TWM2OD14LkG1N|E3KM7:TR?= NIfTdGtUSU6JRWK=
MMAC-SF Mlz1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGD0SFlKSzVyPU[uNVg2PTZizszN NHXaZZRUSU6JRWK=
NCI-H82 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnvXpZFUUN3ME22MlIxPDh7IN88US=> NInGN4tUSU6JRWK=
RS4-11 NY\zS4tsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrNUJZHUUN3ME22MlI2QDl5IN88US=> NV\uWHZFW0GQR1XS
SNU-C2B NEP0b|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDYTWM2OD14LkSwPVY6KM7:TR?= NXnsU3lLW0GQR1XS
BOKU NITy[Y9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTZwNEe1PVch|ryP MX\TRW5ITVJ?
C8166 MkfmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\LbWlEPTB;Nj61OVkyOiEQvF2= MYDTRW5ITVJ?
D-247MG NXvu[Fl1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTdwMESzOFch|ryP MmXQV2FPT0WU
EW-18 NFLD[FVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTdwMEeyPVIh|ryP NYfpS2V2W0GQR1XS
KG-1 Ml\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDwTWM2OD15Lk[yO|M5KM7:TR?= MYPTRW5ITVJ?
REH NWPKOpY1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTWNJVwUUN3ME23MlY5OTB7IN88US=> NGLYVoxUSU6JRWK=
U-698-M MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGj3VoxKSzVyPUeuPFQ{OTVizszN MlHxV2FPT0WU
KP-N-RT-BM-1 M3HCN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHmTWM2OD15LkmzNFI6KM7:TR?= NXyxfG1lW0GQR1XS
MS-1 M3\w[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTdwOU[wOFEh|ryP NF;ROZFUSU6JRWK=
SNU-C1 NUPXdGJFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rTcWlEPTB;Nz65PFE6OiEQvF2= NH[zUolUSU6JRWK=
SK-MM-2 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRThwMk[wOlUh|ryP MmD3V2FPT0WU
LAN-6 MlWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLKTWM2OD16LkOwNFAyKM7:TR?= NETQ[npUSU6JRWK=
NEC8 NVrBNlRUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPR[GZHUUN3ME24MlMxPjlzIN88US=> M3G5b3NCVkeHUh?=
NCI-H1770 M1;MN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLjTWM2OD16LkO4NFAzKM7:TR?= M{PwXHNCVkeHUh?=
D-336MG M3XBXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlT1TWM2OD16LkSwNVE3KM7:TR?= NFiwSHdUSU6JRWK=
COLO-829 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfMTWM2OD16LkS4PFc6KM7:TR?= NV7NVGc{W0GQR1XS
LS-513 M3XK[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGCwfmxKSzVyPUiuOVk2QTlizszN NXjVTFFpW0GQR1XS
YT M{\kNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRThwNkK0Nlch|ryP MkLVV2FPT0WU
EW-24 M2DsOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHX[JV[UUN3ME24Mlc3PTRizszN M1HTPHNCVkeHUh?=
IST-SL1 NY\S[YhST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\3cmlEPTB;OD64OlU1OyEQvF2= NFPoTZlUSU6JRWK=
CA46 NXvWSZZIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRThwOUWwPVgh|ryP MWrTRW5ITVJ?
NCI-H1838 NYXmfnRHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRThwOUi2NFIh|ryP M3;UZ3NCVkeHUh?=
NCI-H719 Ml;iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TmdmlEPTB;OT6yOVI4QSEQvF2= NULsUWd2W0GQR1XS
HCE-T NH\HdZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX70dZg1UUN3ME25MlMxQDVzIN88US=> MYrTRW5ITVJ?
A498 M4LreWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LOPGlEPTB;OT6zOlEzPCEQvF2= M1TWeHNCVkeHUh?=
LB831-BLC NUfMS3hMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NET6UZNKSzVyPUmuO|Y2OjFizszN MXTTRW5ITVJ?
SKM-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\NRnhKSzVyPUmuPFU6PjNizszN MXnTRW5ITVJ?
THP-1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnxeGdKSzVyPUmuPVY6OThizszN MYDTRW5ITVJ?
SHP-77 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF65V3BKSzVyPUGwMlQxPyEQvF2= MYfTRW5ITVJ?
EW-3 Mke4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzKWGJyUUN3ME2xNE43Ojh7IN88US=> MnPRV2FPT0WU
KY821 MmL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXj5TFM1UUN3ME2xNE44PjNizszN MU\TRW5ITVJ?
NCI-SNU-1 NV76fJYxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTFzLkCyNVch|ryP MYTTRW5ITVJ?
HCC2218 M4q4S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTFzLkO5PFYh|ryP MWHTRW5ITVJ?
IM-9 M2LoXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\Mc2lEPTB;MUGuOVExPiEQvF2= M4LlcnNCVkeHUh?=
NCI-H889 NUD6SoxjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnGyTWM2OD1zMT61N|E{KM7:TR?= M1THbXNCVkeHUh?=
HDLM-2 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofLTWM2OD1zMj60NVU6KM7:TR?= NGO2c4ZUSU6JRWK=
LB2518-MEL MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEP2Z4xKSzVyPUGyMlY5OTVizszN MUXTRW5ITVJ?
NCI-H23 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfYPYdKSzVyPUGzMlI1OjVizszN NVGyTlZKW0GQR1XS
NB17 MmqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTF|LkS1O|kh|ryP MmLNV2FPT0WU
NCI-H322M MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTF2LkSwOlgh|ryP NVj3blFZW0GQR1XS
SUP-T1 NH3WSWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3YRVBKSzVyPUG0MlQyOyEQvF2= NHzrUJJUSU6JRWK=
ES3 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHtTWM2OD1zNT6wO|A{KM7:TR?= NI\3NGRUSU6JRWK=
ES5 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;HSHJKSzVyPUG1MlA4QDdizszN M4HtUnNCVkeHUh?=
NCI-H1650 NGO5cmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zqfWlEPTB;MUWuOFk4QSEQvF2= NEjp[4lUSU6JRWK=
NCI-H226 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7vVJF1UUN3ME2xOU45PzZ6IN88US=> NGDtZ3VUSU6JRWK=
COR-L88 MnXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTFTWM2OD1zNj6zNVQh|ryP M3Xjd3NCVkeHUh?=
SCC-15 NFnGNZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPWTWM2OD1zNj6zPFY6KM7:TR?= NFvCS3VUSU6JRWK=
GOTO MmDKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXCdZViUUN3ME2xOk41Pzl|IN88US=> M1PuUXNCVkeHUh?=
SIMA NWHoO2JRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPOZ41KSzVyPUG2MlQ5ODJizszN NXG3XnJSW0GQR1XS
NCI-H1299 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\tTWM2OD1zNz6xOVkyKM7:TR?= NVTxT4tLW0GQR1XS
NCI-H1581 NUHlU4VRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTF5LkSyNVkh|ryP M3HS[nNCVkeHUh?=
MHH-NB-11 M2nWUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHER5hbUUN3ME2xO{46Pjh|IN88US=> NXvKUnhkW0GQR1XS
MFM-223 M1u3dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{CwRmlEPTB;MUiuNFU{QCEQvF2= NXXuSVhGW0GQR1XS
ES7 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\jTWM2OD1zOD61OFMyKM7:TR?= NGL1eWZUSU6JRWK=
JVM-3 MorLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTF6LkexO{DPxE1? NFPmO3ZUSU6JRWK=
RL NFjxOpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjoTWM2OD1{MD6zPFgh|ryP NI\BOIxUSU6JRWK=
EC-GI-10 M1rINmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHHWGNvUUN3ME2yNU4zODRzIN88US=> NF3NSWpUSU6JRWK=
LNCaP-Clone-FGC MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnr3TWM2OD1{MT62O|Y5KM7:TR?= M2P1THNCVkeHUh?=
IMR-5 NYfEOZY6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\QV4xKSzVyPUKxMlg1QTRizszN MYTTRW5ITVJ?
KP-N-YS Ml3HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvQTWM2OD1{MT64O|Uh|ryP NUXQfoRrW0GQR1XS
Mo-T MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2e0T2lEPTB;MkKuNlE5PSEQvF2= NF;qRXBUSU6JRWK=
NCI-H128 MlT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGns[YtKSzVyPUKzMlU5PTNizszN NHLIbm9USU6JRWK=
RH-1 MoTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfpTWM2OD1{Mz63PFY3KM7:TR?= MmjGV2FPT0WU
NCI-H2171 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2f5OGlEPTB;MkSuNlQ5PSEQvF2= M{D1U3NCVkeHUh?=
RPMI-8866 M4nUbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmK2TWM2OD1{Nj63OFIh|ryP M4HLUnNCVkeHUh?=
SK-N-FI NU\oToxxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTNTWM2OD1{Nz6zPFEyKM7:TR?= NFvtZYRUSU6JRWK=
LOXIMVI M4D1T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2O3cGlEPTB;MkeuPFA2OSEQvF2= MoXvV2FPT0WU
P31-FUJ NVP2SpM4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTNzLkWzO|Qh|ryP NXvNe4FIW0GQR1XS
KMS-12-PE MoCwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;TTWM2OD12OT61N|AzKM7:TR?= Mn3ZV2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo試験 Treatment with Rapamycin in vivo specifically blocks targets known to be downstream of mTOR such as the phosphorylation and activation of p70S6K and the release of inhibition of eIF4E by PHAS-1/4E-BP1, leading to complete blockage of the hypertrophic increases in plantaris muscle weight and fibre size. [4] Short-term Rapamycin treatment, even at the lowest dose of 0.16 mg/kg, produces profound inhibition of p70S6K activity, which correlates with increased tumor cell death and necrosis of the Eker renal tumors. [5] Rapamycin inhibits metastatic tumor growth and angiogenesis in CT-26 xenograft models by reducing the production of VEGF and blockage of VEGF-induced endothelial cell signaling. [6] Rapamycin treatment at 4 mg/kg/day significantly reduces tumor growth of C6 xenografts, and tumor vascular permeability. [7]
臨床試験 A Phase II study of Rapamycin to erase angiofibromas in patients with Tuberous Sclerosis Complex (TSC) is currently ongoing.
特集

プロトコル (参考用のみ)

キナーゼアッセイ:

[1]

Immunoblotting for the mTOR kinase assay HEK293 cells are plated at 2-2.5×105 cells/well of a 12-well plate and serum-starved for 24 hours in DMEM. Cells are treated with increasing concentrations of Rapamycin (0.05-50 nM) for 15 minutes at 37 °C. Serum is added to a final concentration of 20% for 30 minutes at 37 °C. Cells are lysed, and cell lysates are separated by SDS-PAGE. Resolved proteins are transferred to a polyvinylidene difluoride membrane and immunoblotted with a phosphospecific primary antibody against Thr-389 of p70 S6 kinase. Data are analyzed using ImageQuant and KaleidaGr

細胞アッセイ:

[3]

細胞株 U87-MG, T98G, and U373-MG
濃度 Dissolved in DMSO, final concentrations ~25 μM
反応時間 72 hours
実験の流れ

Cells are exposed to various concentrations of Rapamycin for 72 hours. For the assessment of cell viability, cells are collected by trypsinization, stained with trypan blue, and the viable cells in each well are counted. For the determination of cell cycle, cells are trypsinized, fixed with 70% ethanol, and stained with propidium iodide using a flow cytometry reagent set. Samples are analyzed for DNA content using a FACScan flow cytometer and CellQuest software. For apoptosis detection, cells are stained with the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) technique using an ApopTag apoptosis detection kit. To detect the development of acidic vesicular organelles (AVO), cells are stained with acridine orange (1 μg/mL) for 15 minutes, and examined under a fluorescence microscope. To quantify the development of AVOs, cells are stained with acridine orange (1 μg/mL) for 15 minutes, removed from the plate with trypsin-EDTA, and analyzed using the FACScan flow cytometer and CellQuest software. To analyze the autophagic process, cells are incubated for 10 minutes with 0.05 mM monodansylcadaverine at 37 °C and are then observed under a fluorescence microscope.

動物実験:

[7]

動物モデル Athymic Nu/Nu mice inoculated subcutaneously with VEGF-A-expressing C6 rat glioma cells
製剤 Dissolved in solvent solution (0.2% carboxymethylcellulose and 0.25% Tween-80 in sterile H2O)
投薬量 ~4 mg/kg/day
投与方法 Injection i.p.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download Rapamycin (Sirolimus) SDF
分子量 914.18
化学式

C51H79NO13

CAS No. 53123-88-9
保管 2年-20℃
6月-80℃in solvent
別名 AY 22989,NSC-2260804
溶解度 (25°C) * In vitro DMSO 20 mg/mL (21.87 mM)
<1 mg/mL (<1 mM)
エタノール <1 mg/mL (<1 mM)
In vivo 0.5% CMC+0.25% Tween 80 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethyl]-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone

カスタマーフィードバック (12)


Click to enlarge
Rating
Source Nat Genet, 2014, 46(4), 364-70. Rapamycin (Sirolimus) purchased from Selleck
Method Western blot
Cell Lines Persister cells
Concentrations 10 nM
Incubation Time 3 days
Results While added with a specific mTOR inhibitor, rapamycin(Rapa), it inhibitied endogenous mTOR activity, showed that markedly reduced MYC protein levels in persister cells but not in naive T-ALL cells.

Click to enlarge
Rating
Source Cancer Cell, 2011, 19(6), 792-804. Rapamycin (Sirolimus) purchased from Selleck
Method Cell viability Analysis
Cell Lines Ar+murine (CaP8) and human (LNCaP) prostate cancer cells, Pb-Cre+;PtenL/L mice, Pb-Cre+;PtenL/L;ArL/Y mice
Concentrations 1 nM, 4 mg/kg
Incubation Time 0-4 weeks
Results These data suggest that CaPs with AR loss have greater reliance upon the PI3K/AKT/mTOR-signaling pathways and that combined AR/androgen blockage in conjunction with PI3K/AKT/mTOR inhibition (by Rapamycin) is more effective for CaPs initiated by PTEN loss or PI3K/AKT activation.

Click to enlarge
Rating
Source Cell Res, 2012, 22(6), 1003-21. Rapamycin (Sirolimus) purchased from Selleck
Method EdU labeling
Cell Lines MCF-7 cells
Concentrations 150 nM
Incubation Time 48 h
Results The punctate structures from SRC-3 or MIF knockdown cells are very similar to that found in cells treated with rapamycin, a known inducer of autophagy.

Click to enlarge
Rating
Source Autophagy, 2015, 11(4), 617-28. Rapamycin (Sirolimus) purchased from Selleck
Method Cell imaging
Cell Lines H4-LC3-GFP cells
Concentrations 200 nM
Incubation Time 24 h
Results Consistent with inhibition of autophagy, the levels of LC3-II were lower and the levels of SQSTM1/p62 were higher in this USP18 knockdown cell line compared to that of control under basal conditions as well as the induced condition after the treatment with rapamycin.

Click to enlarge
Rating
Source Cell Rep, 2015, 10.1016/j.celrep.2015.01.014. Rapamycin (Sirolimus) purchased from Selleck
Method Western blotting
Cell Lines HEK293 cells
Concentrations 250 nM
Incubation Time 24 h
Results Rapamycin virtually abolishes stimulation by Rheb of phospho-S6 kinase and phospho-4EBP1 but has negligible effects on phospho-eIF2a (A). In contrast to phosphorylation of eIF2a, which is not mediated by mTORC1, phosphorylation of other elongation factors does involve mTORC1. Thus, rapamycin prevents phosphorylation of eIF4G and eIF4B, targets of S6K, but not eIF2a (B). By contrast, rapamycin, as expected, abolishes phospho-S6 kinase but fails to influence phospho-eIF2a, phospho-Erk or phospho-Akt (C).

Click to enlarge
Rating
Source Biochem Pharmacol, 2015, 95(3), 156-69. Rapamycin (Sirolimus) purchased from Selleck
Method Immunofluorescence
Cell Lines RAW264.7 cells
Concentrations 10 uM
Incubation Time 16 h
Results It has been reported that autophagy can directly regulate inflammatory responses. To confirm this phenomenon, we pre-treated RAW264.7 cells with 3-MA (an autophagy inhibitor by blocking the class III PI3Ks) or rapamycin (an autophagy inducer by targeting the negative regulators against autophagy as mammalian target of rapamycin (mTOR)), followed by addition of LPS. LPS-induced punctate LC3 was markedly reduced and enhanced in the presence of 3-MA and rapamycin, respectively.

Click to enlarge
Rating
Source Biochem Pharmacol , 2011, 82, 216-226. Rapamycin (Sirolimus) purchased from Selleck
Method Western blot
Cell Lines H1299 cells
Concentrations 2 μM
Incubation Time 48 h
Results RAD001 and other mTOR inhibitors decreased the levels of survivin protein, as assessed by Western blot analysis, without affecting the levels of other IAP members. In addition, combined treatment with sorafenib and mTOR inhibitor Rapamycin and RAD001 decreased survivin expression to a greater extent than treatment with either alone.

Click to enlarge
Rating
Source J Lipid Res, 2011, 52, 1617-1625. Rapamycin (Sirolimus) purchased from Selleck
Method Histological analysis, immunohistochemistry, Liver triglyceride content analysis, real-time PCR
Cell Lines Male SD rats
Concentrations
Incubation Time 7 d
Results To determine the effect of rapamycin, an mTOR inhibitor, in the OA-induced fatty liver, rats were fed 1% OA and administered rapamycin for seven days. OA-induced lipid accumulation was completely inhibited by the treatment with rapamycin (Fig. A). HE and Oil Red O staining of liver sections clearly confi rmed the results (Fig. B). Immunohistochemistry analyses showed signifi cantly repressed SREBP-1 in the rapamycin-cotreatment liver ( Fig. B ). All the downstream effectors of SREBP-1, such as Lxr-α, Acc, Scd-1 and Fas, were consistently suppressed by rapamycin ( Fig. C ).

Click to enlarge
Rating
Source Biochim Biophys Acta, 2013, 1833(3), 652-62. Rapamycin (Sirolimus) purchased from Selleck
Method Measurement of cytosolic free Ca2+concentration ([Ca2+]c )
Cell Lines Human platelets
Concentrations 500 nM
Incubation Time 30 min
Results Rapamycin administration significantly reduced TG-evoked Ca2+ -entry by 19. 5 ?9.4 %.

Click to enlarge
Rating
Source Tuberc Respir Dis, 2013, 75(1), 9-17. Rapamycin (Sirolimus) purchased from Selleck
Method Microscope imaging
Cell Lines NCI-H1299 cells
Concentrations 10 uM
Incubation Time 48 h
Results Growth inhibition induced by rapamycin or erlotinib is enhanced by combination treatment with monensin in NCI-H1299 cells.

Click to enlarge
Rating
Source 2011, Dr.Ulrich Bommer of University of Wollongong. Rapamycin (Sirolimus) purchased from Selleck
Method Western blot
Cell Lines
Concentrations
Incubation Time 0-6 h
Results Rapamycin inhibits growth-dependent TCTP induction.

Click to enlarge
Rating
Source 2013, Dr. Zhang of Tianjin Medical University. Rapamycin (Sirolimus) purchased from Selleck
Method Western Blot
Cell Lines HeLa cells
Concentrations 0/2/20/200 nM
Incubation Time 24 h
Results

文献中の引用 (59)

技術サポート&よくある質問(FAQ)

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の質問がある場合は、お気軽くお問合せください。

* 必須

Related mTOR 阻害剤

  • MHY1485

    MHY1485 is a potent, and cell-permeable mTOR activator, and also potently inhibits autophagy.

  • CHIR-99021 (CT99021)

    CHIR-99021(CT99021)は、GSK-3αとGSK-3β阻害剤で、IC50 がそれぞれ 10 nM と 6.7 nMである。

  • Dorsomorphin

  • Afuresertib (GSK2110183)

    Afuresertib (GSK2110183) is a potent, orally bioavailable Akt inhibitor with Ki of 0.08 nM, 2 nM, and 2.6 nM for Akt1, Akt2, and Akt3, respectively. Phase 2.

  • Everolimus (RAD001)

    Everolimus (RAD001) は、1.6-2.4nMのIC50によるFKBP12のmTOR阻害剤です。

  • AZD8055

    AZD8055は、0.8nMのIC50によるmTORの新しいATP競争的阻害剤です。

    Features:First drug to inhibit both types of mTOR protein.

  • Torin 1

    Torin1は、mTORの強力な阻害剤で、IC50 が 2-10 nMです。

  • Temsirolimus (CCI-779, NSC 683864)

    Temsirolimus (CCI-779, NSC 683864)は、特定のmTOR阻害剤で、IC50 が 1.76 μM。

  • INK 128 (MLN0128)

    INK 128 (MLN0128)は、有力で選択的なmTOR 阻害剤で、 IC50 が 1 nMです。

最近チェックしたアイテム

Tags: Rapamycin (Sirolimus)を買う | Rapamycin (Sirolimus)供給者 | Rapamycin (Sirolimus)を購入する | Rapamycin (Sirolimus)費用 | Rapamycin (Sirolimus)生産者 | オーダーRapamycin (Sirolimus) | Rapamycin (Sirolimus)代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
お問い合わせ